Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
8.98
USD
|
+5.15%
|
|
+3.22%
|
+46.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
204.6
|
499.2
|
193
|
105.1
|
123.9
|
339.1
|
-
|
-
|
Enterprise Value (EV)
1 |
123.8
|
345.2
|
73.88
|
-108.7
|
123.9
|
189.2
|
271.7
|
339.1
|
P/E ratio
|
-1.53
x
|
-4.46
x
|
-2.57
x
|
-0.53
x
|
-1.27
x
|
-3.31
x
|
-3.25
x
|
-4.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
14.2
x
|
13
x
|
-
|
93.5
x
|
68.6
x
|
108
x
|
EV / Revenue
|
-
|
-
|
5.42
x
|
-13.4
x
|
-
|
52.2
x
|
54.9
x
|
108
x
|
EV / EBITDA
|
-1.06
x
|
-4.09
x
|
-
|
-
|
-
|
-1.92
x
|
-2.29
x
|
-4.04
x
|
EV / FCF
|
-1.27
x
|
-6
x
|
-0.93
x
|
1.08
x
|
-
|
-2.49
x
|
-
|
-
|
FCF Yield
|
-78.4%
|
-16.7%
|
-107%
|
92.9%
|
-
|
-40.2%
|
-
|
-
|
Price to Book
|
2.24
x
|
2.98
x
|
0.9
x
|
0.22
x
|
-
|
2.52
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,066
|
4,390
|
7,353
|
19,528
|
20,177
|
37,757
|
-
|
-
|
Reference price
2 |
66.75
|
113.7
|
26.25
|
5.380
|
6.140
|
8.980
|
8.980
|
8.980
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
13.62
|
8.094
|
-
|
3.625
|
4.945
|
3.142
|
EBITDA
1 |
-116.5
|
-84.48
|
-
|
-
|
-
|
-98.64
|
-118.9
|
-83.94
|
EBIT
1 |
-119.3
|
-88.41
|
-72.25
|
-99.27
|
-104.3
|
-102.9
|
-130.5
|
-136.9
|
Operating Margin
|
-
|
-
|
-530.5%
|
-1,226.51%
|
-
|
-2,838.16%
|
-2,638.04%
|
-4,358.54%
|
Earnings before Tax (EBT)
1 |
-117.2
|
-88.29
|
-72.19
|
-85.98
|
-96.02
|
-96.46
|
-124.7
|
-132.7
|
Net income
1 |
-117.2
|
-88.29
|
-72.19
|
-85.98
|
-96.02
|
-95.46
|
-119.5
|
-132.7
|
Net margin
|
-
|
-
|
-530.01%
|
-1,062.28%
|
-
|
-2,633.42%
|
-2,416.83%
|
-4,223.71%
|
EPS
2 |
-43.65
|
-25.50
|
-10.20
|
-10.10
|
-4.830
|
-2.715
|
-2.766
|
-2.213
|
Free Cash Flow
1 |
-97.1
|
-57.5
|
-79.04
|
-101
|
-
|
-76
|
-
|
-
|
FCF margin
|
-
|
-
|
-580.36%
|
-1,247.74%
|
-
|
-2,096.56%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.537
|
3.154
|
1.925
|
6.2
|
-
|
-
|
-
|
-
|
-
|
-
|
0.9062
|
0.9062
|
0.9062
|
0.9062
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18.69
|
-19.01
|
-19.29
|
-19.58
|
-
|
EBIT
1 |
-18.03
|
-18.65
|
-25.37
|
-25.38
|
-21.13
|
-28.91
|
-32.03
|
-26.84
|
-23.11
|
-22.26
|
-22.92
|
-24.09
|
-25.77
|
-26.6
|
-34.2
|
Operating Margin
|
-509.78%
|
-591.38%
|
-1,318.03%
|
-409.39%
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,529.24%
|
-2,657.98%
|
-2,843.9%
|
-2,934.68%
|
-
|
Earnings before Tax (EBT)
1 |
-17.98
|
-18.61
|
-25.33
|
-25.09
|
-20.41
|
-15.15
|
-30.07
|
-24.63
|
-20.98
|
-20.34
|
-21.23
|
-21.54
|
-23.61
|
-24.59
|
-32.43
|
Net income
1 |
-17.98
|
-18.61
|
-25.33
|
-25.1
|
-20.41
|
-15.15
|
-30.07
|
-24.63
|
-21
|
-20.34
|
-20.91
|
-21.46
|
-23.51
|
-24.7
|
-32.43
|
Net margin
|
-508.43%
|
-590.04%
|
-1,315.74%
|
-404.84%
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,307.42%
|
-2,368.51%
|
-2,594.27%
|
-2,725.06%
|
-
|
EPS
2 |
-2.400
|
-2.550
|
-3.300
|
-3.300
|
-2.710
|
-0.6800
|
-1.540
|
-1.250
|
-1.050
|
-1.000
|
-0.5759
|
-0.5744
|
-0.6243
|
-0.6045
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/14/22
|
4/27/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/14/23
|
11/8/23
|
3/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
80.9
|
154
|
119
|
214
|
-
|
150
|
67.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-97.1
|
-57.5
|
-79
|
-101
|
-
|
-76
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-114%
|
-83.2%
|
-42.4%
|
-41%
|
-
|
-50.7%
|
-47.9%
|
-43.1%
|
ROA (Net income/ Total Assets)
|
-96.5%
|
-64.3%
|
-35.8%
|
-34.9%
|
-
|
-45.7%
|
-
|
-
|
Assets
1 |
121.5
|
137.3
|
201.8
|
246.3
|
-
|
208.7
|
-
|
-
|
Book Value Per Share
2 |
29.80
|
38.10
|
29.30
|
24.90
|
-
|
3.570
|
-
|
-
|
Cash Flow per Share
|
-
|
-16.30
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.39
|
0.9
|
1.28
|
3.02
|
-
|
1.21
|
0.43
|
-
|
Capex / Sales
|
-
|
-
|
9.41%
|
37.25%
|
-
|
33.46%
|
8.61%
|
-
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
8.98
USD Average target price
17.78
USD Spread / Average Target +97.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +46.25% | 339M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|